Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 11.28% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 11.28% decrease from a year earlier, with the FY2025 full-year figure at $4.7 million, down 8.39% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.1 million, down from $4.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for DTIL reached as high as $5.2 million in Q3 2022 and fell as low as $1.1 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $3.4 million across 5 years, with a median of $3.5 million in 2023.
• Across the five-year window, Accumulated Expenses advanced 19.74% in 2022 and tumbled 38.05% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $5.1 million in 2022, then fell by 2.47% to $5.0 million in 2023, then gained by 4.1% to $5.2 million in 2024, then decreased by 8.39% to $4.7 million in 2025, then sank by 75.98% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.1 million in Q1 2026, $4.7 million in Q4 2025, and $3.2 million in Q3 2025.